1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6ED55D5EBF95FBDD6002586B80050866C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/ED55D5EBF95FBDD6002586B80050866C?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Product Launch Excellence

Document Excerpt: Pharmaceutical Product Launch Evaluation Excellence: Launch Evaluation Process and Lessons Learned

DB Image

ID: MD-776


Features:

11 Info Graphics

11 Data Graphics

50+ Metrics

14 Narratives


Pages/Slides: 4


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5676 “Pharmaceutical Product Launch Evaluation Excellence: Launch Evaluation Process and Lessons Learned”.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Consumer Products; Chemical; Medical Device; Communications; Consulting


Companies Profiled:
Amgen; Sanofi; Merck; Novartis; Eisai; Genentech; Sunovion; Grünenthal; GlaxoSmithKline ; Novo Nordisk; UCB Pharma; BIOCAD; Sanofi Genzyme; ASC Therapeutics; APR Applied Pharma Research; Prothena; Karyopharm Therapeutics; Alcon; Arvelle Therapeutics; BeiGene; Dendreon; NexGen Healthcare Communications; MEDiSTRAVA; Klosterfrau Healthcare Group; Kala Pharmaceuticals; Inc.; Bioviiix; Nutricia; Scilex Pharmaceuticals; NeuroTau; Medexus Pharmaceuticals; Theravance; Supernus; Viatris

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.